Pharmacology · Year 2 · from Pharmacology

Case 2: Targeted Therapy in HER2-Positive Breast Cancer

Patient Demographics

• Age: 48 years
• Sex: Female
• Occupation: Nurse practitioner

Chief Complaint

"I found a lump in my breast and the biopsy shows cancer."

History of Present Illness

A 48-year-old woman presents after self-detecting a left breast mass during self-examination. Mammogram and ultrasound confirmed a 2.5 cm spiculated mass in the upper outer quadrant with suspicious axillary lymph nodes. Core needle biopsy revealed invasive ductal carcinoma. Pathology shows: Grade 3, ER-negative, PR-negative, HER2-positive (IHC 3+ confirmed by FISH with HER2/CEP17 ratio 4.2). PET-CT staging shows no distant metastases.

Final Staging

• Clinical Stage: IIB (T2N1M0)
• Tumor Characteristics: Triple-negative for hormone receptors, HER2-positive
• Grade: 3 (poorly differentiated)

Understanding HER2 Biology

What is HER2?

• Human Epidermal Growth Factor Receptor 2
• Member of ErbB receptor tyrosine kinase family
• Overexpressed/amplified in ~15-20% of breast cancers
• Associated with aggressive tumor behavior

HER2 Signaling Pathway:

1. HER2 dimerizes with other ErbB family members (HER1, HER3, HER4)
2. Activates downstream signaling cascades:

• RAS/MAPK pathway (proliferation)
• PI3K/AKT pathway (survival, anti-apoptosis)

1. Results in increased cell proliferation, survival, and metastatic potential

HER2 Testing:

This patient is IHC 3+ with FISH ratio 4.2 = Strongly HER2-positive

Treatment Plan

Neoadjuvant (Pre-Surgical) Chemotherapy + HER2-Targeted Therapy:

TCHP Regimen (every 3 weeks x 6 cycles):

• Docetaxel (T): 75 mg/m2 IV - Taxane (microtubule stabilizer)
• Carboplatin (C): AUC 6 IV - Platinum (DNA crosslinker)
• Trastuzumab (H): 8 mg/kg loading, then 6 mg/kg IV - Anti-HER2 antibody
• Pertuzumab (P): 840 mg loading, then 420 mg IV - Anti-HER2 antibody

Understanding HER2-Targeted Agents

1. Trastuzumab (Herceptin) - Monoclonal Antibody

Mechanism:

• Binds to extracellular domain IV of HER2 receptor
• Prevents HER2 dimerization and downstream signaling
• Induces antibody-dependent cellular cytotoxicity (ADCC)
• Downregulates HER2 receptor expression
• Inhibits cleavage of HER2 extracellular domain

Key Toxicity: CARDIOTOXICITY

• Mechanism: HER2 signaling important for cardiomyocyte survival
• Manifests as decreased LVEF, heart failure
• Usually reversible (unlike anthracycline cardiotoxicity)
• Monitoring: Echocardiogram or MUGA before starting and every 3 months
• Hold if LVEF drops >= 16% from baseline or below normal with >= 10% drop

2. Pertuzumab (Perjeta) - Monoclonal Antibody

Mechanism:

• Binds to extracellular domain II of HER2 (different epitope than trastuzumab)
• Prevents HER2 heterodimerization with HER3
• Complementary to trastuzumab: "Dual HER2 blockade"
• Also induces ADCC

Key Points:

• Used in combination with trastuzumab (not monotherapy)
• Improves pathologic complete response rates in neoadjuvant setting
• Improves survival in metastatic setting
• Similar cardiac monitoring as trastuzumab

3. Additional HER2-Targeted Agents (For Reference):

ADC = Antibody-Drug Conjugate:

• Monoclonal antibody linked to cytotoxic payload
• Antibody targets cancer cell
• Internalized, releases chemotherapy inside cell
• "Targeted chemotherapy delivery"

Pre-Treatment Workup

Required Before Starting TCHP:

1. Echocardiogram: LVEF 62% (normal >= 50%)
2. CBC, CMP: Normal
3. Hepatitis B serology: Negative (trastuzumab can cause reactivation)
4. Fertility counseling: Chemotherapy causes ovarian toxicity; discuss egg preservation

Treatment Course

Neoadjuvant Therapy Completed:

• 6 cycles TCHP completed
• Tolerated well; mild nausea, fatigue, neuropathy
• Repeat echo after cycle 3 and 6: LVEF stable at 58%

Surgery:

• Lumpectomy + sentinel lymph node biopsy
• Pathology: Complete pathologic response (pCR) - No residual invasive cancer
• pCR is associated with excellent long-term outcomes in HER2+ disease

Adjuvant (Post-Surgical) Therapy:

• Continue trastuzumab + pertuzumab to complete 1 year of HER2-targeted therapy
• Radiation therapy to breast
• No hormonal therapy needed (ER/PR negative)

Monitoring and Follow-up

Cardiac Monitoring:

• Echo every 3 months during HER2-targeted therapy
• Continue monitoring 6-12 months after completion

If LVEF Decreases:

• Drop of >= 16% from baseline OR
• LVEF below normal with >= 10% drop
• Hold trastuzumab/pertuzumab
• Repeat echo in 4 weeks
• Can rechallenge if LVEF recovers
• Consider cardiology consultation, start ACE inhibitor/beta-blocker

Clinical Pearl

HER2-positive breast cancer, once associated with poor prognosis, has been transformed by HER2-targeted therapies. Trastuzumab revolutionized treatment and significantly improved survival. Adding pertuzumab provides "dual HER2 blockade" by binding different epitopes and preventing HER2/HER3 dimerization. Pathologic complete response (no residual invasive cancer after neoadjuvant therapy) is a strong predictor of excellent outcomes. The main toxicity concern with HER2-targeted antibodies is cardiotoxicity, requiring regular LVEF monitoring. Unlike anthracycline-induced cardiomyopathy (permanent damage via oxidative stress), trastuzumab cardiotoxicity is usually reversible with drug interruption. For patients who progress on trastuzumab, antibody-drug conjugates (T-DM1, T-DXd) deliver cytotoxic payloads directly to HER2-expressing cells.

Clinical Image

Immunohistochemistry staining for HER2 in breast cancer tissue. HER2 3+ staining shows strong complete membrane staining, indicating HER2 overexpression and eligibility for HER2-targeted therapy.

Image Source: Wikimedia Commons - "HER2 immunohistochemistry" License: CC BY-SA 4.0 URL: https://commons.wikimedia.org/wiki/File:HER2_immunohistochemistry.jpg

All cases for this lecture as Markdown